The Unseen Tariff on Public Health
Connect these dots: CASE A: The NHS-US Drug Deal (2026-2029) The Financial Times article highlights a £1 billion commitment by the NHS over three years to secure drugs from US suppliers. Sir Patrick Vallance, the UK's former Chief Scientific Adviser, now confirmed as chair of the Department of Health's Procurement Review Board, suggests this spending will be absorbed within existing departmental
budgets. The framing emphasizes cost management within the existing framework. CASE B: The Transatlantic Trade and Investment Partnership (TTIP) Negotiations (2013-2016) During the TTIP negotiations, a critical concern for UK public health advocates centered on clauses related to 'market access' for foreign companies, particularly within healthcare sectors. Documents released by the European
Commission in 2014, for example, contained explicit proposals for 'state-owned enterprises' (SOEs) – a category that could encompass the NHS – to operate under 'commercial considerations' and 'non-discriminatory treatment' for private, foreign providers (European Commission, 2014). This explicitly aimed to prevent public entities from favoring domestic suppliers or public provision. THE FRAMING: A
'Deal' vs. A 'Structural Shift' The current coverage presents the £1 billion expenditure as an isolated 'drugs deal,' a pragmatic response to supply chain needs or innovation. It avoids framing it within the broader historical ambition of US trade negotiators to open up foreign public services – particularly healthcare – to American corporate interests. The language used by proponents during TTIP,